To analyze the incidence of intraocular pressure (IOP) elevation following int ravitreal triamcinolone injection. Retrospective observational case series. Char ts of patients undergoing intravitreal triamcinolone injection in one clinical p ractice were reviewed. A pressure elevation was defined as a pressure of 24 mm H g or higher during follow up. There were 89 patients with a mean age of 76.4 ye ars. The mean baseline IOP was 14.9 mm Hg with a mean change of 8.0 mm Hg. Thirt y six patients (40.4%) experienced a pressure elevation to 24 mm Hg or higher at a mean of 100.6 days (SD= 83.1 day) after treatment. Of nonglaucomatous patie nts with baseline IOP of 15 mm Hg or above, 60.0%experienced a pressure elevati on, compared with only 22.7%of those with baseline pressures below 15 mm Hg (re lative risk=2.1, P< .01). In glaucoma patients, 6 of 12 (50%) experienced a pre ssure elevation, and this elevation was not correlated with baseline pressure. T hirty two patients (36.0%) received repeat injections, and there was no differ ence in the incidence of procedure elevation in patients receiving multiple inje ctions versus those receiving a single injection. Pressure elevation was control led with topical medications in all patients. IOP elevation after intravitreal t riamcinolone injection is common and may take an extended period of time to mani fest. The proportion of patients who developed a pressure elevation to at least 24 mm Hg was much higher for those with baseline IOP 15 mm Hg or greater. To analyze the incidence of intraocular pressure (IOP) elevation following int ravitreal triamcinolone injection. Retrospective observational case series. Char ts of patients undergoing intravitreal triamcinolone injection in one clinical p ractice were reviewed. A pressure elevation was defined as a pressure of 24 mm H There were 89 patients with a mean age of 76.4 ye ars. The mean baseline IOP was 14.9 mm Hg with a mean change of 8.0 mm Hg. Thirty six patients (40.4%) experienced a pressure elevation to 24 mm Hg or higher at a mean of 100.6 days (SD = 83.1 day) after treatment. Of nonglaucomatous patie nts with baseline IOP of 15 mm Hg or above, 60.0% experienced a pressure elevati on, compared with only 22.7% of those with In glaucoma patients, 6 of 12 (50%) experienced a pre ssure elevation, and this elevation was not correlated with baseline pressure. Thirty two patients (re lative risk = 2.1, P <.01) (36.0%) received r epeat injections, and there was no differ ence in the incidence of procedure elevation in patients receiving multiple inje ctions versus those receiving a single injection. Pressure elevation was control led with topical medications in all patients. IOP elevation after intravitreal t riamcinolone injection is common and the proportion of patients who developed a pressure elevation to at least 24 mm Hg was much higher for those with baseline IOP 15 mm Hg or greater.